"Study Finds Frailty and Sarcopenia Linked to Clinical Worsening During Leqembi Treatment"
Korea University Guro Hospital Analyzes 187 Patients with Early Alzheimer's Disease
Cognitive and Daily Living Functions Worsened More Rapidly in Patients with Frailty and Sarcopenia
No Significant Difference in Changes in Blood Biomarker p-tau217
A research team at Korea University Guro Hospital has found that physical frailty and sarcopenia in patients receiving Leqembi, an Alzheimer's disease treatment, are associated with worsening clinical outcomes during treatment. Patients with physical frailty were also found to experience more infusion-related reactions.
Korea University Guro Hospital announced on October 29 that a research team led by Professor Kang Seonghun of the Department of Neurology had published these findings in the online edition of the international journal Aging and Disease.
From left: Kang Seonghun, professor of neurology at Korea University Guro Hospital; resident Shin Jaemin; and researcher Park Yujeong. Korea University Guro Hospital
View original imageThe research team analyzed 187 patients with early Alzheimer's disease who began Leqembi treatment between December 2024 and May 2026, using K-LEARN, a prospective, real-world cohort established by Korea University Guro Hospital. The team assessed physical frailty and sarcopenia before treatment and tracked changes in cognitive function, clinical outcomes, adverse reactions, and blood biomarkers during treatment.
Physical frailty was measured using the Short Physical Performance Battery (SPPB), which assesses balance, walking speed, and the ability to rise from a chair. Sarcopenia was assessed according to the Asian Working Group for Sarcopenia criteria (AWGS 2019). Of the 187 patients analyzed, 52 (27.8%) had physical frailty and 63 (33.7%) had sarcopenia.
The analysis found that patients with physical frailty or sarcopenia before treatment showed a faster worsening in their Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores than patients without either condition. CDR-SB is a measure that comprehensively assesses cognitive function and the ability to perform activities of daily living. This association remained even after adjusting for age, sex, education level, apolipoprotein E (APOE) genotype, and clinical severity before treatment.
Patients with physical frailty also had a higher incidence of Leqembi infusion-related reactions (IRRs). Infusion-related reactions occurred in 20 of 52 patients with frailty (38.5%), compared with 23 of 135 patients without frailty (17.0%). An analysis adjusted for major clinical factors also found a significant association between physical frailty and infusion-related reactions.
By contrast, changes in p-tau217, a blood biomarker, did not differ significantly according to whether patients had physical frailty or sarcopenia. p-tau217 is a blood biomarker associated with the pathological changes of Alzheimer's disease. The research team said that differences in clinical outcomes associated with physical vulnerability were not reflected in changes in p-tau217.
Professor Kang Seonghun said, "In this study, patients with physical frailty and sarcopenia experienced faster worsening of clinical symptoms, but there was no significant difference in changes in p-tau217. When seeking to understand outcomes in patients receiving Leqembi, we should consider not only amyloid pathology but also their overall physical condition." He added, "Along with tracking cognitive function, brain imaging, and blood biomarkers during Leqembi treatment, it is necessary to assess physical functions such as walking, balance, and strength and incorporate the results into individualized care plans."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This study was observational and had no untreated control group, so it did not establish a causal relationship showing that physical frailty or sarcopenia directly alters the effectiveness of Leqembi treatment. The research team plans to investigate whether improving physical function through exercise and nutritional management can help improve clinical outcomes during treatment.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.